Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes

Biochemical Pharmacology

Volumn 57, Issue 11, 1999, Pages 1227-1232

  Perloff, Michael D ^a   Von Moltke, Lisa L ^a   Cotreau, Monette M ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytochrome P450 3A; Dexamethasone; mdr1 gene; Midazolam; P glycoprotein; Triazolam

Indexed keywords

CYTOCHROME P450; DEXAMETHASONE; GLYCOPROTEIN P; MIDAZOLAM; TRIAZOLAM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; IMMUNOREACTIVITY; LIVER MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; BLOTTING, WESTERN; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; MICE; MICROSOMES, LIVER; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; TRIAZOLAM;

EID: 0033152397     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00054-4     Document Type: Article

References (30)

1. Borst P., Schinkel A.H., Smit J.J., Wagenaar E., Van Deemter L., Smith A.J., Eijdems E.W., Baas F., Zaman G.J. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther. 60:1993;289-299.
2. Silverman J.A., Schrenk D. Hepatic canalicular membrane 4 Expression of the multidrug resistance genes in the liver . FASEB J. 11:1997;308-313.
3. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 97:1996;2517-2524.
4. Gottesman M.M., Pastan I., Ambudkar S.V. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev. 6:1996;610-617.
5. Wacher V.J., Wu C.Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein Implications for drug delivery and activity in cancer chemotherapy . Mol Carcinog. 13:1995;129-134.
6. Watkins P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Delivery Rev. 27:1997;161-170.
7. Schinkel A.H., Smit J.J.M., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A.A.M., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P.J., Berns A.J.M., Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
8. Wacher V.J., Salphati L., Benet L.Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Delivery Rev. 20:1996;99-112.
9. Tsui L.C., Donis-Keller H., Grzeschik K.H. Report of the second international workshop on human chromosome 7 mapping 1994. Cytogenet Cell Genet. 71:1995;2-21.
10. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 49:1996;311-318.
11. Lee C.H., Bradley G., Zhang J.T., Ling V. Differential expression of P-glycoprotein genes in primary rat hepatocyte culture. J Cell Physiol. 157:1993;392-402.
12. Salphati L., Benet L.Z. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol. 55:1998;387-395.
13. Schuetz E.G., Schinkel A.H., Relling M.V., Schuetz J.D. P-glycoprotein A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans . Proc Natl Acad Sci USA. 93:1996;4001-4005.
14. Ford J.M., Hait W.N. Pharmacologic circumvention of multidrug resistance. Cytotechnology. 12:1993;171-212.
15. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 96:1995;1698-1705.
16. von Moltke L.L., Granda B.W., Grassi J.M., Greenblatt D.J. Multiple site interaction of triazolam and ketoconazole in mice Role of P-glycoprotein . Clin Pharmacol Ther. 65:1999;143.
17. von Moltke L.L., Greenblatt D.J., Harmatz J.S., Shader R.I. Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes . Pharmacology. 47:1993;268-276.
18. von Moltke L.L., Greenblatt D.J., Schmider J., Duan S.X., Wright C.E., Harmatz J.S., Shader R.I. Midazolam hydroxylation by human liver microsomes in vitro Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents . J Clin Pharmacol. 36:1996;783-791.
19. Fahey J.M., Pritchard G.A., Moltke L.L., Pratt J.S., Grassi J.M., Shader R.I., Greenblatt D.J. Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. J Pharmacol Exp Ther. 285:1998;271-276.
20. Kronbach T., Mathys D., Umeno M., Gonzalez F.J., Meyer U.A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol. 36:1989;89-96.
21. Segel I.H. Enzyme Kinetics. 1975;Wiley, New York.
22. Laemmli V.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
23. Ghosal A., Satoh H., Thomas P.E., Bush E., Moore D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA expressed human cytochrome P450. Drug Metab Dispos. 24:1996;940-947.
24. von Moltke L.L., Greenblatt D.J., Harmatz J.S., Duan S.X., Harrel L.M., Cotreau-Bibbo M.M., Pritchard G.A., Wright C.E., Shader R.I. Triazolam biotransformation by human liver microsomes in vitro Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole . J Pharmacol Exp Ther. 276:1996;370-379.
25. Tomlinson E.S., Maggs J.L., Park B.K., Back D.J. Dexamethasone metabolism in vitro: Species differences . J Steroid Biochem Mol Biol. 62:1997;345-352.
26. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.L., Turgeon D.K., Schmiedlin-Ren P., Brown M.B., Guo W., Rossi S.J., Benet L.Z., Watkins P.B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 62:1997;248-260.
27. Haehner B.D., Gorski J.C., Vandenbranden M., Wrighton S.A., Janardan S.K., Watkins P.B., Hall S.D. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol. 50:1996;52-59.
28. Pfeil D., Bergmann J., Fichtner I., Stein U., Hentschel M., Rothe I., Goan S.R. Multidrug resistance of murine leukemia cells characterization and correlation with cytochrome P-450 dependent activities, cytosolic calcium and cell cycle state. Anticancer Res. 14:1994;571-576.
29. 1) . Biochim Biophys Acta. 1201:1994;405-410.
30. Yanagimoto T., Itoh S., Muller-Enoch D., Kamataki T. Mouse liver cytochrome P-450 (P-450IIIAm1) Its cDNA cloning and inducibility by dexamethasone . Biochim Biophys Acta. 1130:1992;329-332.